随着现代医学的发展，抗真菌药物广泛应用，白假丝酵母(又称白念珠菌)耐药现象日益严重。由酵母相转变为菌丝相是白念珠菌致病的一个必要过程，抑制菌丝形成可控制其感染。细菌群体感应信号分子BDSF(顺十二碳­-2-­烯酸)可抑制这一形态的转变，从而抑制白念珠菌的致病力。本研究检测BDSF对60株白念珠菌临床菌株的抑菌丝效果，同时测定这60株临床菌株对氟康唑的敏感度。结果显示，60株临床菌株中8株(13.3%)对氟康唑耐药，最低抑菌浓度(MIC)≥64 μg/ml，而BDSF对耐与不耐氟康唑的临床菌株均能高效抑制菌丝生长。结果表明，BDSF可作为临床治疗白念珠菌感染的新型候选药物，值得进一步研究。

The drug resistance of Candida albicans (C. albicans), resulted from gradual application of advanced medical treatments and the widespread use of antifungals, has become a severe problem in clinic. C. albicans is one of the major opportunistic human fungal pathogens. The transition from yeast to hypha is a necessary process in its pathogenic activity, and inhibiting the hypha formation can decrease its infective ability. Quorum sensing signal BDSF (short­-chain fatty acid) from Burkholderiacenocepacia can inhibit the yeast­to­hypha transition and hinder the virulence of C. albicans. The drug susceptibility of 60 C.albicans clinical isolates to fluconazole and BDSF were determined respectively. The results showed there were 8 strains (13.3%) resistant to fluconazole, with the minimum inhibitory concentration (MIC) ≥64 μg/ml, but BDSF showed efficiently inhibitory effect on all the clinical isolates no matter the isolates were resistant to fluconazole or not. The results suggest that BDSF might be a new clinical option to treat C. albicans infection.